Physician profile
William P Wright
NPI 1962475848
$20,993.01
in general payments reported to CMS, 2019-2025
30 companies · $2,384 in 2025
The $2,384 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,839 · 2020: $1,412 · 2021: $1,223 · 2022: $4,889 · 2023: $1,862 · 2024: $2,384 · 2025: $2,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,986 · Travel and Lodging: $612 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,986.14 |
| Travel and Lodging | $611.83 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $5,643.50 | 2019-2020 | |
| Abbott Laboratories | $4,632.74 | 2021-2025 | Aveir, Gallant, Jot Dx |
| Boston Scientific Corporation | $4,576.70 | 2019-2025 | Resonate El Icd Vr, General - Crm_crm, S-Icd System Magnet |
| Medtronic, INC. | $3,291.56 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Cvrx, INC. | $540.37 | 2021-2025 | Barostim Neo System |
| Abiomed | $286.64 | 2021-2023 | Impella |
| Astrazeneca Pharmaceuticals Lp | $263.42 | 2024-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $229.65 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $175.94 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.22 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $160.50 | 2024-2025 | Verquvo, Capvaxive |
| Angiodynamics, INC. | $140.27 | 2024 | Auryon Laser System 100-120 Vac |
| Inspire Medical Systems, INC. | $120.54 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $96.92 | 2024-2025 | |
| Cardiac Dimensions, INC. | $90.42 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $83.00 | 2022-2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $70.44 | 2024-2025 | Eliquis, Camzyos |
| Pfizer INC. | $66.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.04 | 2024-2025 | |
| Esperion Therapeutics, INC. | $51.83 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $37.12 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $35.89 | 2024 | |
| Resmed Corp | $34.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $29.28 | 2019-2020 | |
| Biocompatibles, INC. | $23.76 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.13 | 2024 | Arcalyst |
| Surgenex LLC | $19.41 | 2025 | Surmatrix, Pellograft, Renograft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.99 | 2025 | Jardiance |
| Philips North America LLC | $15.94 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.